New research paper featured on the cover aging (Listed as “Aging (Albany, NY)” in MEDLINE/PubMed and “Aging – USA” in Web of Science) Volume 16, Issue 3, Title: “GV1001 Enhances the 3xTg-AD Mouse Model Through Anti-Aging” “effects that reduce neurodegeneration and extend lifespan.” ”
GV1001, which mimics the activity of human telomerase reverse transcriptase, protects neurons from amyloid beta (Aβ) toxicity and other stressors through extratelomere function, as noted in our previous in vitro studies . It improves cognitive function in patients with moderate to severe dementia, according to a recent Phase II clinical trial. However, the underlying protective mechanisms remain unclear.
In this new study, researchers Park Hyun Hee, Hyuk Sung Geun, Lee Kyu Young, Kim Ye Eun, Son Jung Woo, Choi Na Young, Han Myung Hoon, Park Dong Woo, Kim Sang Jae, and Go Seong-ho Researchers from Hanyang University Guri Hospital, Hanyang University School of Biomedical Engineering, and Teloid Inc. set out to investigate the effects of GV1001 on neurodegeneration, aging, and survival in triple transgenic Alzheimer’s disease (AD) (3xTg-AD) mice. I made it my purpose.
” […] We hypothesized that GV1001 has anti-aging effects and may ameliorate neurodegeneration and aging in vivo as a possible mechanism by which GV1001 may exert its beneficial effects on AD. . ”
GV1001 (1 mg/kg) was injected subcutaneously into old 3xTg-AD mice three times per week until the end point of sacrifice, and survival was analyzed. To assess the entry of GV1001 into the brain, magnetic resonance imaging (MRI) and Prussian blue staining (PBS) were performed. To investigate the effects of GV1001 on neurodegeneration and cellular senescence in AD model mice, we specifically focused on BACE, amyloid beta 1-42 (Aβ1-42), phosphorylated tau, dentate gyrus volume, and β-galactosidase positivity. A variety of molecular studies have been carried out. cells, telomere length, telomerase activity, and aging-related proteins.
GV1001 crossed the blood-brain barrier as confirmed by assessing the status of ferrocene carboxylic acid-bound GV1001 using magnetic resonance imaging and PBS. GV1001 prolonged survival of her 3xTg-AD mice. It has been shown that BACE and Aβ1-42 levels, neurodegeneration (i.e., decreased CA1, CA3 and dentate gyrus volumes, decreased levels of aging-associated β-galactosidase-positive cells, increased telomere length and telomerase activity), and aging-associated Reduced protein levels. .
“GV1001 exerts anti-aging effects in 3xTg-AD mice by reducing neurodegeneration and aging, which may contribute to improved survival rates.”
sauce:
Reference magazines:
Park, H.-H. other. (2024). GV1001 attenuates neurodegeneration and extends lifespan in his 3xTg-AD mouse model with anti-aging effects. aging. doi.org/10.18632/aging.205489.
